UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE …

UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE Curriculum Vitae

Date: 07/19/2021

Lynn Mara Schuchter, M.D.

Address: Division of Hematology Oncology

Perelman Center for Advanced Medicine If you are not a U.S. citizen or holder of a permanent visa, please indicate the type of visa you have: none (U.S. citizen) Education: 1978 B.S. University of Michigan 1982 M.D. Chicago Medical School Postgraduate Training and Fellowship Appointments: 1982-1983 Intern, Department of Medicine, Michael Reese Hospital,

Chicago, IL 1983-1985 Resident, Department of Medicine, Michael Reese Hospital,

Chicago, IL 1985-1986 Chief Medical Resident, Department of Medicine, Michael

Reese Hospital, Chicago, IL 1986-1989 Clinical Fellow, Medical Oncology, The Johns Hopkins

Oncology Center Baltimore, MD 1987 Visiting Fellow, Biologic Response Modifier Program, NCI,

Frederick, MD 2016-2018 Hospice & Palliative Medicine Fellowship, Hospital of the

University of Pennsylvania, Philadelphia, PA Military Service: [none] Faculty Appointments: 1989-1995 Assistant Professor of Medicine, University of Pennsylvania

School of Medicine 1995-1996 Assistant Professor of Medicine at the Hospital of the

University of Pennsylvania, University of Pennsylvania School of Medicine

1996-2006 Associate Professor of Medicine at the Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine

2006-2011 Professor of Medicine at the Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine

2011-present C. Willard Robinson Professor of Hematology-Oncology, University of Pennsylvania School of Medicine


Hospital and/or Administrative Appointments: 1985-1986 Clinical Instructor, Department of Medicine, University of

Chicago Hospital and Clinics 1985-1986 Associate Attending Physician, Department of Medicine,

Michael Reese Hospital 1989-present Attending Physician, Hospital of the University of

Pennsylvania 2007-2008 Interim Division Chief-Hematology/Oncology, University of

Pennsylvania 2008-present Division Chief, Hematology-Oncology, University of

Pennsylvania 2018-present Director, Tara Miller Melanoma Center, Abramson Cancer

Center Other Appointments: 1992-2008 Director, Clinical Research Unit, Abramson Cancer Center of

the University of Pennsylvania 1994-2003 Co-Program Leader, Clinical Investigations Program,

Abramson Cancer Center of the University of Pennsylvania 2003-2007 Program Leader, Clinical Investigations Program, Abramson

Cancer Center of the University of Pennsylvania 2007-2018 Program Leader: Melanoma Program, Abramson Cancer

Center of the University of Pennsylvania 2009-2011 Associate Director, Clinical Research Unit, Abramson Cancer

Center of the Hospital of the University of Pennsylvania 2016-present Internal Advisory Board Member, University of Pennsylvania

Center for Health Incentives and Behavioral Economics 2017-present Internal Advisory Board Member, Palliative and Advanced

Illness Research Center (PAIR) Specialty Certification: 1986 American Board of Internal Medicine (Internal Medicine) 1990 American Board of Internal Medicine Subspecialty

Certification in Medical Oncology 2018 American Board of Internal Medicine (Hospice & Palliative

Medicine) Licensure: 1989 License to Practice Medicine, State of Pennsylvania Awards, Honors and Membership in Honorary Societies: 1981 Alpha Omega Alpha 1985 A.A. Goldsmith Humanitarian Award, Michael Reese Hospital 1986-1987 Clinical Fellowship Award, American Cancer Society 1988-1989 Trainee, National Research Service Award


1991-1993 American Cancer Society: Career Development Award 1995 John Glick Teaching Award 2005-present Best Doctors in America 2007 Riza Lavizzo-Mourey Visiting Professorship

Department of Medicine 2007 Susan Fazio Award for Melanoma Research 2013 Humanitarian Award, Melanoma Research Foundation -

Wings of Hope for Melanoma Philadelphia 2014 Louis Duhring Outstanding Clinical Specialist Award - Penn

Medicine 2017 FOCUS Award for the Advancement of Women in

Medicine/Perelman School of Medicine at the University of Pennsylvania

2017 Women on the Move/Main Line Today, Newtown Square, PA 2017 Abramson Cancer Center Philly Fights Cancer: Round 3 -

Honoree 2019 Hologic, Inc Endowed Women Who Conquer Cancer

Mentorship Award/ Conquer Cancer The ASCO Foundation Women Who Conquer Cancer

2020 Provider Patient Experience Champion of the Year/Clinical Practices of the Hospital of the University of Pennsylvania (CPUP)

Memberships in Professional and Scientific Societies and Other Professional Activities: College of Physicians, Philadelphia (Member) Society of Biological Therapy (Member, 1991-1995) Society of Melanoma Research (Member-2004) National: 1989-Present American Society of Clinical Oncology (ASCO) (Member, 1989

Board of Directors: 2009 - 2012 Board of Directors: Education Subcommittee 2009-2012 Board of Directors: Planning Subcommittee 2009-2012 Cancer.Net Advisory Panel: 2008 Timely Oncology Perspectives (TOPs)Team 2009-2013) ASCO-SSO Sentinel Node Biopsy (SNB) in Melanoma Member 2008-2018 Cancer Research Committee: 2004-present Cancer Research Audit Committee: 2009-2010 Cancer Research Strategic Planning: 2009-2012 Cancer Research Committee, Chair: 2013-2014


Co-Chair- Chemo/Radio Protectants Expert Panel: 1998-2012 ASCO Maintenance of Certification Task Force: 2005-2007 Scientific Program Committee Subcommittee Chair: 1992,1994,1996,1997,2003-2005,2014-present Scientific Program Committee Chair: 2015 Education Committee: 1995,1996,1997,2003-2004 Public Issues Committee:2002-2004 Chair:2003-2004 Cancer Communication Committee: 1993-1998 Vice Chairman: 1994-1996 Chairman: 1996-1998 Board Liaison: 2009-2012 Executive Editor: 2013-2014 News Planning Team, Chair: 2016 inaugural ASCO-SITC Clinical Immuno-Oncology Symposium)

1992-2005 American College of Physicians (Member, 1992

PIER Review: Melanoma Module) 1993-Present Membership in National Scientific Review Panels:

National Institutes of Health (ad hoc Member, NIH, CTEP, Grant Reviewer 1992, 1993 ad hoc Member, NIH, GCRC, Grant Reviewer 1993, 1994, 1995, 1996 ad hoc Member, NIH, RFA, Grant Reviewer 1994 ad hoc Member, NIH, POI, Grant Reviewer 1995 ad Hoc Member, FDA Orphan Drug Program1995 ad Hoc Member, NIH POI, Grant Reviewer1995 NIH Clinical Oncology Study Section - Member1999-2000 NCI IRG-Subcommittee A for Cancer Center Reviews Study Section effective 7/1/05-present ad Hoc Reviewer, NCI SPORE Grant Review-2007)


1995-2002 American Board of Internal Medicine (Secretary, Subspecialty Committee in Medical

Oncology) SEP Medical Oncology: Committee 2006)

2006-Present Melanoma Research Foundation: Member (Scientific Advisory Committee: Member

and Past Chair, Board of Directors: Former Board Member)

Editorial Positions: 1992-1997 Medical Editor, University of Pennsylvania Cancer Center

Newsletter 1994-1997 PDQ Editorial Board, NCI 1994-1998 Editorial Member, Journal of Clinical Oncology 1995-2011 Editor: Melanoma Section, Current Opinion in Oncology 1999-2003 Editor: Skin Cancer, Current Treatment Options in Oncology 2005-2008 Editor, Journal of Clinical Oncology 2005-2007 Editorial Board: Journal of Clinical Oncology 2009-2012 Associate Editor, Cancer.Net American Society of Clinical

Oncology (ASCO) Academic and Institutional Committees: 1990-2005 General-Clinical Research Center (GCRC) Advisory Committee

Member Vice Chair: 2003-2005

1993-Present Clinical Trials Scientific Review and Monitoring Committee: Cancer Center Vice-Chairman 1993-1995 Chairman 1995-1997 Chair-Auditing subcommittee 1997-2001

1995-1997 Drug and Usage Subcommittee Member 1995-1999 Institute for Human Gene Therapy (Member) 1995-1996 Patient Oriented Research Task Force 1997-1999 Intern Selection Committee 1999-2009 University Research Foundation Committee 2002-2008 Faculty Advisory Committee-Office of Human Research 2002-2006 University of Pennsylvania IRB

Vice Chair: 2004-2005 Chair: IRB-2005-2006

2004-2005 Committee to Review Epidemiology and Biostatistics Graduate Group

2006-2009 Advisory Committee on Women: Dept of Medicine 2006-2010 Clinical Research Advisory Committee-Member: Executive

Committee 2007-2008 Department of Medicine COAP-member


2008-Present Member, Perelman Center for Advanced Medicine - Physicians

Governance Committee 2009-Present Executive Steering Committee, Abramson Cancer Center at the

University of Pennsylvania 2010-Present Executive Committee, Perelman Center for Advanced Medicine -

Cancer Service Line 2010-Present Co-leader, Hematology/Oncology Quality Cancer Care Committee 2017-Present Member, Business Development Committee - Regional Cancer

Program 2018-Present Executive Committee, Penn Medicine and Penn Princeton Cancer

Program 2019-Present Member, Diversity Equity Inclusion Committee, Penn Hematology

Oncology Major Academic and Clinical Teaching Responsibilities: 1990-Present Supervision of Medical Oncology Fellows in Weekly Clinic 1997-Present Adult Oncology Nurse Practitioner Course

N666 Nursing Management and the Effects of Cancer and Cancer Therapy University of Pennsylvania School of Nursing Biotherapy, Vaccine Therapy, and Gene Therapy

2002 Clinical Applications of Oncology Drugs First Year Medical Students

2003-2004 Doctoring I 2003-2004 GCP: Introduction to Patient Oriented Research

School of Medicine 2004-2009 EP: Phase II Clinical Trial Design 2007-2008 LEAP: First Year Medical Students: 2007-2009 EP: Conducting Clinical Research: Good Clinical Practice

Course to Fellows in Conduct of Clinical Research 2007-Present Supervision of First Year Medicine Intern in Outpatient Oncology

Practice 2018 Roy and Diana Vagelos Program in Life Science and Management

(LSM) "Decision Resources Lecture in Life Sciences and Management" Distinguished Lecturer

Lectures by Invitation (Last 5 years): Jan, 2016 "New immunotherapy approaches for the treatment of melanoma -

Can advanced melanoma be cured?" The Children's Hospital of Philadelphia, Philadelphia, PA

May, 2016 "Curing advanced melanoma: Becoming a real possibility" Wills Eye Hospital Intraocular Tumor Symposium, Philadelphia, PA

May, 2016 "Putting it All Together: What every patient should know about Melanoma" Penn Medicine, Abramson Cancer Center, Focus on Melanoma, Philadelphia, PA

Sep, 2016 Metastatic Melanoma Potentially Curable? Cancer Symposium,


Doylestown Health, Doylestown Hospital, Doylestown, PA

Sep, 2016 "Managing Common Dose-Limiting Toxicities" ASCO Palliative Care in Oncology Symposium, San Francisco, CA

May, 2017 "Focus on Melanoma" Nov, 2017 "Recent Advances in Oncology for the Primary Care Physician -

Virtua", Penn Medicine, Abramson Cancer Center of the University of Pennsylvania

Oct, 2018 "Confronting Melanoma in all its Forms and Stages" Keynote - Melanoma Action Coalition Fall Conference, Philadelphia, PA

Nov, 2018 "Cutaneous Oncology"/Sixteenth Wallace H. Clark Jr., MD Lectureship in Cutaneous Oncology/University of Pennsylvania

Dec, 2018 "Penn Medicine Inaugural Student Clinician's Ceremony Oct, 2019 "Reflection on a 30 Year Career" The Conquer Cancer Foundation

of ASCO, 2019 Conquer Cancer Scientific and Career Development Retreat, Washington, DC

Jun, 2020 "Impact of COVID-19 on the Delivery of Cancer Care / Cancer and COVID-19: Update from Penn's Abramson Cancer Center"

Oct, 2020 "A Decade of Advancement: Harnessing the Patient Immune System" LEAD Conference for Women in Oncology, Bio Ascend, a Vaniam Group Company, Virtual

Dec, 2020 "Understanding New Approached to Cancer Treatment - Targeted Therapy and Immunotherapy / Recent Advance in Oncology 2020 Virtual Meeting

May, 2021 "18th Focus on Melanoma" Penn Medicine, Abramson Cancer Center, Virtual

Organizing Roles in Scientific Meetings: Nov, 2007 Society of Melanoma Research Melanoma Congress

Chairman and Moderator of Clinical/Translational Melanoma Session New York, NY

Apr, 2008 Translational Research: Focus Melanoma AACR Annual Meeting Session Co-Chair San Diego, CA

Sep, 2008 Oncology Congress: Melanoma Session San Francisco, CA

Mar, 2013 Planning Committee member and speaker, Recent Advances in Oncology for the Primary Care Physician. Abramson Cancer Center of the University of Pennsylvania. Valley Forge, PA

Jun, 2013 Planning Committee Member and Speaker, 2013 Updates in Oncology: With Proceedings from International Medical Meetings. Perelman School of Medicine of the University of Pennsylvania Philadelphia, PA

Nov, 2018 Activity Co-Director 16th Wallace H. Clark Jr., MD Lectureship in


Cutaneous Oncology & Melanoma Symposium Clark Lectureship: Adjuvant Therapy for Melanoma: Head-spinning Progress Penn Medicine's Abramson Cancer Center, Arthur Rubenstein Auditorium, Philadelphia, PA

Jun, 2019 Co-Director, Updates in Oncology 2019 Philadelphia with Proceeding from International Medical Meetings The Rittenhouse Hotel, Philadelphia PA

Nov, 2019 Co-Chair/A Seat at the Table-Removing Barriers and Bias for Women in Oncology Penn Medicine/Abramson Cancer Center, Philadelphia, PA

Sep, 2020 Co-Conference Chair, CANCER and COVID-19: Update from Penn's Abramson Cancer Center University of Pennsylvania/Abramson Cancer Center / Philadelphia, PA Virtual

Sep, 2020 Chair/Cancer and COVID-19: Update from Penn's Abramson Cancer Center University of Pennsylvania/Abramson Cancer Center/ Philadelphia, PA Virtual

Oct, 2020 Co-Chair, Conquer Cancer The ASCO Foundation, Women Who Conquer Cancer, LEAD Conference for Women in Oncology Virtual

Nov, 2020 Host/Women Who Conquer Cancer Philadelphia, PA Virtual

2020 Activity Co-Director/Recent Advances in Oncology 2020 Virtual Meeting University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

May, 2021 Conference Chair, 18th Focus on Melanoma Virtual

Bibliography: Research Publications, peer reviewed (print or other media): 1. Schuchter, L.M., Wingard, J.R., Piantadosi, S., Burns, W.H., Santos, G.W., Saral, R.:

Herpes Zoster Infection Following Autologous Bone Marrow Transplantation. Blood 74(4): 1424-1427, 1989.

2. Fishman, E.K, Kuhlman, J.E., Schuchter, L.M., Miller, J.A., Magid, D.: CT of

Malignant Melanoma in the Chest, Abdomen and Musculoskeletal System. Radiographics 10(4): 603-620, 1990.

3. Schuchter, L.M, Hendricks, C.B., Holland, K.H., Shelton, B.K., Hutchins, G.M.,

Baugham, K.G., Ettinger, D.S.: Eosinophilic Myocarditis Following Interleukin-2 Treatment. Am J of Med 88(4): 439-440, 1990.

4. Kawashima, A., Fishman, E.K., Kuhlman, J.E., Schuchter, L.M.: CT of Malignant


Melanoma: Patterns of Small Bowel and Mesenteric Involvement. Journal of Computer Assistant Tomography 15(4): 570-574, 1991.

5. Schuchter, L.M., Esa, A.H., May, W.S., Pettit, G.R., Laulis, M.K., Hess, A.D.:

Successful Treatment of Murine Melanoma with Bryostatin-1. Cancer Res 51: 682-687, 1991.

6. Meropol, N.J., Miller, L., Korn, E.L., Braitman, L.E., MacDermott, M.L., Schuchter,

L.M.: Severe Myelosuppression Resulting from Concurrent Administration of Granulocyte Colony-Stimulating Factor and Cytotoxic Chemotherapy. J Natl Cancer Inst 84(15): 1201-1203, 1992.

7. Redmond, H.P., Schuchter, L.M., Bartlett, D., Kelly, C.J., Shou, J., Leon, P., Daly,

J.M.: Anti-Neoplastic Effects of Interleukin-4. J Surg Res 52(4): 406-411, 1992. 8. Schuchter, L.M., Wohlganger, J., MacDermott, M., Fishman, E., McGuire, W.P.:

Sequential Chemotherapy and Immunotherapy for the Treatment of Metastatic Melanoma. J Immunother 12(4): 272-276, 1992.

9. Halpern, A.C., Schuchter, L.M., Elder, D.E., Guerry, D., Elenitsas, R., Trock, B.,

Matozzo, I.: Effects of Topical Tretinoin on Dysplastic Nevi. J Clin Oncol 12(5): 1028-1035, 1994.

10. Nakashima, M., Janiszewska, M., Steplewski, Z., Watanabe, T., Schuchter, L.,

Koprowski, H.: Proliferation, Phenotype, and Cytotoxicity of Human Lymphocytes Isolated from Lymph Nodes Invaded by Melanoma Cells. Hybridoma 13(3): 241-246, 1994.

11. Nakashima, M., Watanabe, T., Koprowski, H., Schuchter, L., Steplewski, Z.: In Vitro

Expansion of Tumor Specific, HLA-Restricted CD8+ Cytolytic T-lymphocytes. Cellular Immunology 155(1): 53-61, 1994.

12. Einzig, A.I., Schuchter, L.M., Rodriguez, R., Coatsworth, S., Wiernik, P.H., Recio,

A.: Phase II Trial of Docetaxel (Taxotere) in Patients with Metastatic Melanoma Previously Untreated with Cytotoxic Chemotherapy. Medical Oncology 13(2): 111-117, 1996.

13. Greco, F.A., Figlin, R., York, M., Einhorn, L., Schilsky, R., Marchsll, E.M., Buys,

S.S., Froimtchuk, M.J., Schuller, J., Schuchter, L., Buyse, M., Ritter, L., Man, A., Yap, A.K.: Phase III Tandomized Study to Compare Interferon Alfa-2A in Combination with Fluorouracil versus Fluorouracil Alone in Patients with Advanced Colorectal Cancer. J Clin Oncol 14(10): 2674-2681, 1996.

14. Martenseon, J.A., Lipsitz, S.R., Wagner, H., Kaplan, E.H., Otteman, L.A., Schuchter,

L.M., Mansour, E.G., Talamonti, M.S., Benson, A.B.: Initial Results of a Phase II Trial of High Dose Radiation Therapy, 5 Fluorouracil and Cisplatin for Patients


with Anal Cancer (E4292): An Eastern Cooperative Oncology Group Study. Int J Radia Oncol Biol Phys 35(4): 745-749, 1996.

15. Schuchter, L.M., Schultz, D.J., Synnestevdt, M., Trock, B.J., Guerry, D., Elder, D.,

Elenitsas, R., Clark, W.H., Halpern, A.C.: A Prognostic Model Predicting 10 Year Survival in Patients with Primary Melanoma. The Pigmented Lesion Group. Ann Intern Med 125(5): 369-375, 1996.

16. Anbari, K., Schuchter, L.M., Bucky, L., Mick, R., Synnestvedt, M., Guerry, D.,

Hamilton, R., Halpern, A.: Melanoma of Unknown Primary Site: Presentation, Treatment and Prognosis in a Single Institution Study, University of Pennsylvania Pigmented Lesion Study Group. Cancer 79(9): 1816-1821, 1997.

17. Berd, D., Maguire, H.C., Schuchter, L.M., Hamilton, R., Hauck, W.W., Mastrangelo,

M., Sato, T.: Autologous Hapten-Modified Melanoma Vaccine as Post-Surgical Adjuvant Treatment After Resection of Nodal Metastases. J Clin Oncol 15(6): 2359-2370, 1997.

18. Alpaugh, R.K., von Mehren, M., Palazzo, I., Atkins, M., Sparano, J.A., Schuchter, L.,

Weiner, L., Dutcher, J.P.: Phase IB Trial for Malignant Melanoma Using R24 Monoclonal Antibody, Interleukin-2/alpha Interferon. Medical Oncology 15(3): 191-198, 1998.

19. DiPaola, R., Goudins, S., Rodriquez, R., Orlick, M., Mollman, J., Bird, S., Belsh, J.,

Schuchter, L.M.: Amifostine and Dose Intensive Paclitaxel in Patients with Advanced Malignancies. Cancer Therapeutics 1: 11-17, 1998.

20. Margolis, D.J., Halpern, A.C., Rebbeck, T., Schuchter, L., Barnhill, R.L., Fine, J.,

Berwick, M.: Validation of a Melanoma Prognostic Model. Arch Dermatol 134(2): 1597-1601, 1998.

21. Chapman, P.B., Einhorn, L.H., Meyers, M.L., Saxman, S., Destro, A.N., Panageas,

K.S., Begg, C.B., Arawala, S.S., Schuchter, L.M., Ernstoff, M.S., Houghton, A.N., Kirkwood, J.M.: Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients with Metastatic Melanoma. J Clin Oncol 17(a): 2745-2751, 1999.

22. Hensley, M.L., Schuchter, L.M., Lindley, C., Meropol, N.J., Cohen, G.I., Groder, G.,

Gradishar, W.J., Green, D.M., Langdon, R.J., Mitchell, R.B., Negrin, R., Szatrowski, T.P., Thigpen, J.T., Von Hoff, D., Wasseman, T.H., Winer, E.P., Pfister, D.G.: American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol 17(10): 3333-3355, 1999.

23. Moore, H.C.F., Mick, R., Solin, L., Sickles, C., Mangan, P., Luger, S., Fox, K.R.,

Schuchter, L.M., Loh, E., Porter, D., Schuster, S., Buzby, G., Glatstein, E.,


Silberstein, L., Stadtmauer, E.: Autologous Stem-Cell Transplant After Conventional Dose Adjuvant Chemotherapy for High-Risk Breast Cancer: Impact on the Delivery of Local-Regional Radiation Therapy. Ann Oncol 10(8): 929-936, 1999.

24. Orel, S.G., Weinstein, S.P., Schnall, M.D., Reynolds, C.A., Schuchter, L., Fraker, D.,

Solin, L.: Breast MR Imaging in Patients with Axillary Node Metastases and Unknown Primary Malignancy. Radiology 212(2): 543-549, 1999.

25. Stadtmauer, E.A., Tsai, D.E., Sickles, C.M., Mick, R., Luger, S.M., Porter, D.L.,

Mangan, P., Schuchter, L.M., Schuster, S., Loh, E., Magee, D., Sachs, R., Wall, M., Moore, J., Buzby, G., Zaleta, E., Kamoun, M., Silberstein, L.: Stem Cell Transplantation for Metastatic Breast Cancer: Analysis of Tumor Contamination. Medical Oncology 16(4): 279-288, 1999.

26. Van Belle, P.A., Elenitsas, R., Satyamoorthy, K., Wolfe, J.T., Guerry, D. 4th,

Schuchter, L., Van Belle, T.J., Albelda, S., Tahin, P., Herlyn, M., Elder, D.E.: Progression-Related Expression of Beta3 Integrin in Melanomas and Nevi. Hum Pathol 30(5): 562-567, 1999.

27. Bedrosian, I., Sheff, A.M., Callans, L.S., Spitz, R.F., Mick, R., Guerry, D., IV,

Schuchter, L., Elenitsas, R., Elder D.E., Bucky, L.P., Fraker, D.L., Czerniecki, B.J.: Incidence of Sentinel Node Metastases in Patients with Thin Primary Melanoma (< or = 1 mm) with Vertical Growth Phase. Ann Surg Oncol 4: 262-267, 2000.

28. Visonneau, S., Caesano, A., Porter, D.L., Luger, S.L., Schuchter, L., Kamoun, M.,

Torosian, M.H., Duffy, K., Sickles, C., Stadtmauer, E., Santoli, D.: Phase I Trial of TALL-104 Cells in Patients with Refractory Metastatic Breast Cancer. Clin Cancer Res 6: 1744-1754, 2000.

29. Chang, J.H., Vines, E., Bertsch, H., Fraker, D.L., Czerniecki, B.J., Rosato, E.F.,

Lawton, T., Conant, E.F., Orel, S.G., Schuchter, L., Fox, K.R., Zieber, N., Glick, J., H., Solin, L.J.: The Impact of a Multidisciplinary Breast Cancer Center on Recommendations for Patient Management: The University of Pennsylvania Experience. Cancer 91: 1231-1237, 2001.

30. Wildemore, J.K. 4th, Schuchter, L., Mick, R., Synnestvedt, M., Elenitsas, R.,

Bedrosian, I., Czerniecki, B.J., Guerry D. 4th, Lessin, S.R., Elder, D.E., Bucky, L.P.: Locally Recurrent Malignant Melanoma Characteristics and Outcomes: A Single-Institution Study. Ann Plast Surg 46(5): 488-494, 2001.

31. Miller, K.D., Gradishar, W., Schuchter, L., Sparano, J.A., Cobleigh, M., Robert, N.,

Rasmussen, H., Sledge, G.W.: A Randomized Phase II Pilot Trial of Adjuvant Marimastat in Patients with Early-Stage Breast Cancer. Ann Oncol 13(8): 1220-1224, August 2002.


32. Anderson, T.D., Weber, R.S., Guerry, D., Elder, D., Schuchter, L., Loevner, L.,

Rosenthal, D.I.: Desmoplastic Neurotropic Melanoma of the Head and Neck: The Role of Radiation Therapy. Head Neck 24(12): 1068-1071, December 2002.

33. Blackwood, M.A., Holmes, R., Synnestvedt, M., Young, M., George, C., Yang, H.,

Elder, D.E., Schuchter, L.M., Guerry, D., Ganguly, A.: Multiple Primary Melanoma Revisited. Cancer 94(8): 2248-2255, 2002.

34. McGinnis, K.S., Lessin, S.R., Elder, D.E., Guerry IV, D., Schuchter, L.M., Elenitsas,

R: Pathology Review of Cases Presenting to a Multidisciplinary Pigmented Lesion Clinic. Arch Dermatol 138(5): 617-621, 2002.

35. Rebbeck, T.R., Kanetsky, P.A., Walker, A.H., Holmes, R., Halpern, A.C., Schuchter,

L.M., Elder, D.E., Guerry, D.: P Gene as an Inherited Biomarker of Human Eye Color. Cancer Epidemiol Biomarkers Prev 11(8): 782-794, 2002.

36. Schuchter, L.M., Hensley M.L., Meropol, N.J., Winder, E.P.: 2002 Update of the

Recommendations for the use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 20(12): 2895-2903, 2002.

37. Stevenson, J.P., Sun, W., Gallagher, M., Johnson, R., Vaughn, D., Schuchter, L.,

Algazy, K., Hahn, S., Enas, N., Ellis, D., Thornton, D., O'Dwyer, P.J.: Phase I Trial of the Cryptophycin Analogue LY355703 Administered as an Intravenous Infusion on a Day 1 and 8 Schedule every 21 days. Clin Cancer Res 8(8): 2524-2529, 2002.

38. Loren, A.W., Desai, S., Gorman, R.C., Schuchter, L.M.: Retransplantation of a

Cardiac Allograft Inadvertently Harvested from a Donor with Metastatic Melanoma. Transplantation 76(4): 741-743, August 2003.

39. Lichtenthal, W.G., Cruess, D.G., Schuchter, L.M., Ming, M.E.: Psychosocial Factors

Related to the Correspondence of Recipient and Provider Perceptions of Social Support Among Patients Diagnosed with or at Risk for Malignant Melanoma. Journal of Health Psychology 8(6): 705-719, 2003.

40. Schuchter LM.: Adjuvant interferon therapy for melanoma: high-dose, no dose,

which dose? J Clin Oncol. 22(1): 7-10, Jan 2004. 41. Kanetsky PA, Ge F, Najarian D, Swoyer J, Panossian S, Schuchter L, Holmes R,

GUerry D, Rebbeck TR.: Assessment of polymorphic variants in the melnaocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach. Cancer Epidemiol Biomarkers Prev. 13(5): 808-19, May 2004.

42. Gimotty, P.A., Guerry, D., Ming, M., Elenitsas, R., Xu, G., Czerniecki, B., Spitz, F.,


Schuchter, L., Elder, D.: Thin Primary Cutaneous Malignant Melanoma: A Prognostic Tree for Ten-Year Metastasis is More Accurate than AJCC Staging. Journal of Clinical Oncology 22(18): 3668-76, Sept 2004.

43. Fuster, D., Chiang, S., Johnson, G., Schuchter, L.M., Zhuang, H., Alavi, A.: Is 18F-

FDG PET More Accurate Than Standard Diagnostic Procedures in the Detection of Suspected Recurrent Melanoma? Journal of Nuclear Medicine 45(8): 1323-1327, 2004.

44. Kanetsky, P., Ge F., Najarian, D., Swoyer, J., Panossian, S., Schuchter, L., Holmes,

R., Guerry, D., Rebbeck, T.R.: Assessment of Polymorphic Variants in the Melanocortin-1 Receptor Gene with Cutaneous Pigmentation Using an Evolutionary Approach. Cancer Epidemiol Biomarkers Prev 13(5): 808-819, 2004.

45. Smith, K, Wray L, Klein-Cabral, M, Schuchter L, Fox K, Glick J, DeMichele A.:

Ethnic Disparities in Adjuvant Chemotherapy for Breast Cancer are not Caused by Excess Toxicity in Black Patients. Clinical Breast 6(3): 260-266, August 2005.

46. Zhang, T, Somasundaram, T, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S,

Schuchter L, Fraker D, Spitz F, Berencsi P, Marincola F, Qui R, Herlyn D.: Preferential Involvement of CX-Chemokine Receptor and CX-Chemokine Ligand -12 in T-cell Migration Toward Melanoma Cells. Journal of Leucocyte Biology Oct 2005.

47. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri

GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ. American Society of Clinical Oncology.: Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 24((1)): 190-205, Jan 2006.

48. Jackson BM, Kim S, Davidson, R, Schuchter L, Acs G, Czerniecki BJ.: Repeat

operative sentinel lymph node biopsy. Clin Breast Cancer. PMID, 6((6)): 530-2, Feb 2006.

49. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P,

Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D.: Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 66((6)): 3287-93, Mar 2006.

50. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, Van Belle P,

Hotz S, Elder DE, Marcinola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D.: Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 66((6)): 3287-93, March 2006.


51. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S,

James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ.: Sorafenib in advanced melanoma: a Phase II randomized discontinuation trial analysis. Br J Cancer 95((5)): 581-6, Sept 2006.

52. Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, Czerniecki

B, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R, Herlyn D.: Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells. Cancer Biol Ther. Epub 2006 Oct 4, 5((10)): 1304-12, Oct 2006.

53. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME,

Schuchter L, Spitz FR, Czerniecki BJ, Guerry D.: Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. (eds.). 25(9): 1129-34, Mar 2007.

54. Swoboda RK, Somasundaram R, Caputo L Ochoa EM, Gimotty PA, Marcinola FM,

Van Belle P, Barth S, Elder D, Guerry D, Czerniecki B, Schuchter, L, Vonderheide RH, Herlyn D.: Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display. Cancer Res 67(8): 3555-9, Apr 2007.

55. Domchek SM, Recio A, Mick R, Clark CE, Carpenter EL, Fox KR, DeMichele A,

Schuchter LM, Leibowitz MS, Wexler MH, Vance BA, Beatty GL, Veloso E, Feldman MD, Vonderheide RH: Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Research 67(21): 10546-55, Nov 1 2007.

56. Gralow Julie, Ozols Robert F, Bajorin Dean F, Cheson Bruce D, Sandler Howard M,

Winer Eric P, Bonner James, Demetri George D, Curran Walter, Ganz Patricia A, Kramer Barnett S, Kris Mark G, Markman Maurie, Mayer Robert J, Raghavan Derek, Ramsey Scott, Reaman Gregory H, Sawaya Raymond, Schuchter Lynn M, Sweetenham John W, Vahdat Linda T, Davidson Nancy E, Schilsky Richard L, Lichter Allen S, : Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of Clinical Oncology 26(2): 313-25, Jan 2008.

57. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C,

Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ: A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Research 14(15): 4836-42, Aug 2008.

58. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH,


Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT, Trotti A, von Hoff D, Schuchter LM: American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27(1): 127-45, Jan 2009.

59. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan

DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH: Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Research 15(13): 4277-87, Jul 2009.

60. Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K,

Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O'Dwyer PJ, Flaherty KT: Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Research 15(24): 7711-7718, Dec 2009.

61. Chakravarthy A, Catalano PJ, Martenson JA, Mondschein JK, Wagner H, Schuchter

LM, Mansour EG , Talamonti MS, Benson AB : Long-term Follow-up of ECOG E4292: A Phase II Trial of High Dose Radiation with Concurrent 5-Fluorouracil and Cisplatin in Patients with Anal Cancer International Journal of Radiation Oncology Biology Physics 75(3 Suppl. S): S27-S27, 2009.

62. Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J,

Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B: Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 27(35): 6052-69, Dec 2009.

63. Kanetsky PA, Panossian S, Elder DE, Guerry D, Ming ME, Schuchter L, Rebbeck

TR.: Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer. 116(10): 2416-28, May 2010.

64. Bajaj NS, Watt C, Hadjiliadis D, Gillespie C, Haas AR, Pochettino A, Mendez J,

Sterman DH, Schuchter LM, Christie JD, Lee JC, Ahya VN: Donor transmission of malignant melanoma in a lung transplant recipient 32 years after curative resection. Transp Int 23(7): e26-31, Jul 2010.

65. Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE,

Shoulson I; PSG PRECEPT Investigators, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C: Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 25(12): 1801-8, Sept 2010

66. Yun SJ, Gimotty PA, Hwang WT, Dawson P, Van Belle P, Elder DE, Elenitsas R,


Schuchter L, Zhang PJ, Guerry D, Xu X: High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma. Am J Surg Pathol 35(2): 235-42, Feb 2011.

67. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R,

Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364(26): 2507-16, June 2011.

68. Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ:

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 68(5): 1111-8, Nov 2011 Notes: Epub 2011 Feb 25.

69. Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, Schuchter L, Xu X.: L8

and Cathepsin B as Melanoma Serum Biomarkers. Int J Mol Sci. 12(3): 1505-18, 2011.

70. Xu X, Chen L, Guerry D, Dawson PR, Hwang WT, VanBelle P, Elder DE, Zhang PJ,

Ming ME, Schuchter L, Gimotty PA.: Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 18(1): 229-37, Jan 2012.

71. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur

GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A.: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366(8): 707-14, Feb 2012.

72. Heaton PC, Schuchter J, Lannon CM, Kemper AR.: Impact of drug label changes on

propofol use in pediatrics for moderate conscious sedation. Clin Ther. 33(7): 229-37, July 2012.

73. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN,

Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH; American Society of Clinical Oncology; Society of Surgical Oncology.: Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 30(23): 2912-8, Aug 2012.


Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH.: Sentinel lymph node biopsy for melanoma: American


Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol. (11), 3313-24, Oct 2012.

75. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O,

Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 367(18): 1694-703, Nov 2012.

76. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan

S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M.: Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 67(6): 1265-72, Dec 2012.

77. Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M,

Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP: Functional profiling of live melanoma samples using a novel automated platform. PLoS One 7(12), 2012.

78. Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB,

Leming P, Kirkwood JM.: Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 31(3): 373-9, Jan 2013 Notes: Epub 2012 Dec 17.

79. Glanz K, Volpicelli K, Kanetsky PA, Ming ME, Schuchter LM, Jepson C, Domchek

SM, Armstrong K.: Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev. 22(459): 607-14, Apr 2013 Notes: Epub 2013 Feb 7.

80. Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, Le K, Amaravadi RK,

Karakousis GC, Xu X, Xu W, Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE: Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest. 123(5): 2155-68, May 2013.

81. Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm

CD, Schuchter LM, Rathmell WK: Physician and stakeholder perceptions of conflict of interest policies in oncology. J Clin Oncol. 31(13): 1677-82, May 2013 Notes: Epub 2013 Mar 25.

82. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE,

Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 31(14): 1767-


74, May 2013.

83. Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B,

Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL.: Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 4(6): 1090-9, September 2013.

84. Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, Xu X,

Elder DE, Ming M, Elenitsas R, Guerry D, Kelz RR, Czerniecki BJ, Fraker DL, Karakousis GC.: Clark Level Risk Stratifies Patients with Mitogenic Thin Melanomas for Sentinel Lymph Node Biopsy. Ann Surg Oncol. October 2013.

85. Cintolo JA, Gimotty P, Blair A, Guerry D, Elder DE, Hammond R, Elenitsas R, Xu

X, Fraker D, Schuchter LM, Czerniecki BJ, Karakousis G.: Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol. 20(11): 3610-7, October 2013 Notes: Epub 2013 Jul 10.

86. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L,

Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT.: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. October 2013 Notes: Epub ahead of print.

87. Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash

O, Schuchter L, Amaravadi R, Xu X, Herlyn M, Nathanson KL, Diehl JA.: The FBXO4 Tumor Suppressor Functions as a Barrier to BrafV600E-Dependent Metastatic Melanoma. Mol Cell Biol. 33(22): 4422-33, November 2013.

88. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L,

Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT.: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 3(12): 1378-93, Dec 2013.

89. Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL,

Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, Flaherty K, Cranmer L, Hodi FS, Day BM, Linke R, Hainsworth J: A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J Page: 18-24, Jan-Feb 2014.


90. Bartlett EK, Gimotty PA, Sinnamon AJ, Wachtel H, Roses RE, Schuchter L, Xu X,

Elder DE, Ming M, Elenitsas R, Guerry D, Kelz RR, Czerniecki BJ, Fraker DL, Karakousis GC.: Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol Page: 643-9, Feb 2014.

91. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu

J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK.: Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest. 124(3): 1406-17, March 2014.

92. Dutcher JP, Neuberg D, Atkins MB, Tester WJ, Wadler S, Stewart JA, Chachoua A,

Schuchter LM.: Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution. J Interferon Cytokine Res 34(5): 376-84, May 2014.

93. Wilson MA, Morrissette JJ, McGettigan S, Roth D, Elder D, Schuchter LM, Daber

RD.: What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing. Cancer Genet. 207(6): 272-5, Jun 2014.

94. Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM,

Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL: Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 20(12): 3328-37, June 2014.

95. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM,

Torigian DA, Panosian JT, Troxel AB, Tan KS, Heitjan DF, DeMichele AM, Vaughn DJ, Redlinger M, Alavi A, Kaiser J, Pontiggia L, Davis LE, O'Dwyer PJ, Amaravadi RK: Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10(8): 1391-402, Aug 2014.

96. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS,

Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O'Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK.: Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10(8): 1369-79, Aug 2014.

97. Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C,

Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH.: Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and


metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res. 2(11): 1051-8, Nov 2014.

98. Gormley R, Wanat K, Elenitsas R, Giles J, McGettigan S, Schuchter L, Takeshita J.:

Ipilimumab-associated Sweet syndrome in a melanoma patient. J Am Acad Dermatol 71(5): 211-3, Nov 2014.

99. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O,

Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R.: Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 32(33): 3697-704, Nov 2014.

100. Lam L, Czerniecki BJ, Fitzpatrick E, Xu S, Schuchter L, Xu X, Zhang H.:

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer. J Mol Biomark Diagn Nov 2014.

101. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante

JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A.: Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial. Ann Oncol. Nov 2014.

102. Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA Iiii, Carducci MA,

Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM: American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. J Clin Oncol Dec 2014.

103. Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA 4th, Carducci MA,

Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM: American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol 33(3): 278-84, Jan 2015.

104. Glanz K, Volpicelli K, Jepson C, Ming ME, Schuchter LM, Armstrong K.: Effects

of Tailored Risk Communications for Skin Cancer Prevention and Detection: The PennSCAPE Randomized Trial. Cancer Epidemiol Biomarkers Prev 24(2): 415-21, Feb 2015.

105. Tao Wang, Min Xiao, Yingbin Ge, Clemens Krepler, Eric Belser, Alfonso Lopez-

Coral, Xiaowei Xu, Gao Zhang, Rikka Azuma, Qin Liu, Rui Liu, Ling Li, Ravi K. Amaravadi, Wei Xu, Giorgos Karakousis, Tara C. Gangadhar, Lynn M. Schuchter, Melissa Lieu, Sanika Khare, Molly B. Halloran, Meenhard Herlyn,


Russel E. Kaufman: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res 21(7): 1652-1664, Apr 2015.

106. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E,

Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547): 373-7, Apr 2015.

107. Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G,

Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis G, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res 21(7): 1652-64, Apr 2015.

108. Gangadhar TC, Schuchter LM.: Broad Applicability of Nivolumab in Melanoma

Regardless of BRAF Mutation Status. JAMA Oncol. 1(4): 427-8, Jul 2015. 109. Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher

M, Chen H, Sehgal C, O'Dwyer PJ.: Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. Oncologist 20(8): 952-9, Aug 2015.

110. Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino

MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR.: Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clin Cancer Res 21(23), Dec 2015.

111. Novel risk scores for survival and intracranial failure in patients treated with

radiosurgery alone to melanoma brain metastases.: Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiat Oncol. Dec 2015.

112. Ravi K. Amaravadi, Kathryn E. Hamilton, Xiaohong Ma, Shengfu Piao, Armando

Del Portillo, Katherine L. Nathanson, Matteo S. Carlino, Georgina V. Long, Igor Puzanov, Xiaowei Xu, Jennifer J.D. Morrissette, Kenneth Y. Tsai, Keith T. Flaherty, Jeffrey A. Sosman, Grant R. Goodman, Grant A. McArthur, Anil K. Rustgi, David C. Metz, Lynn M. Schuchter, Paul B. Chapman, Antonia R. Sepulveda: Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clin Cancer Res. 21(23): 5215-5221, Dec 2015.

113. Melissa A. Wilson, Fengmin Zhao, Sanika Khare, Jason Roszik, Scott E. Woodman,

Kurt D'Andrea, Bradley Wubbenhorst, David L. Rimm, John M. Kirkwood,


Harriet M. Kluger, Lynn M. Schuchter, Sandra J. Lee, Keith T. Flaherty, Katherine L. Nathanson: Copy number changes are associated with response to treatment with carboplatin, paclitaxel and sorafenib in melanoma. Clin Cancer Res 22(2): 374-382, Jan 2016.

114. Shah NN, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers

JS.: Improving the Safety of Oral Chemotherapy at an Academic Medical Center. J Oncol Pract. 12(1), Jan 2016.

115. Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst

B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL.: Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22((2)): 374-82, Jan 2016.

116. Xu MJ, Dorsey JF, Amaravadi R, Karakousis G, Simone CB 2nd, Xu X, Xu W,

Carpenter EL, Schuchter L, Kao GD.: Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients with Melanoma. Oncologist 21(1): 84-94, Jan 2016.

117. Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G,

Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res. Feb 2016.

118. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid

O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT.: Overall Survival and Durable Responses in Patients with BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined with Trametinib. J Clin Oncol. 34(8): 871-8, Mar 2016.

119. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W,

Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M: Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 22(7): 1592-602, April 2016.

120. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X,

Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M.: Targeting mitochondrial biogenesis to


overcome drug resistance to MAPK inhibitors. J Clin Invest. April 2016.

121. Budina-Kolomets A, Webster MR, Leu JI, Jennis M, Krepler C, Guerrini A,

Kossenkov AV, Xu W, Karakousis GC, Schuchter LM, Amaravadi RK, Wu H, Yin X, Liu Q, Lu Y, Mills GB, Xu X, George DL, Weeraratna AT, Murphy ME.: HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors. Cancer Res. 76(9): 2720-30, May 2016.

122. Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu

L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W.: Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep. 15(9): 2012-24, May 2016.

123. Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G,

Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment Cell Melanoma Res. 29(3): 317-28, May 2016.

124. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X,

Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M.: Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5), May 2016.

125. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA,

Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.: The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 29(4): 401-16, Jul 2016.

126. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP,

Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 17(7): 943-55, July 2016.

127. Dai J, Tetzlaff MT, Schuchter LM, Elder DE, Elenitsas R: Histopathologic and


mutational analysis of a case of blue nevus-like melanoma. J Cutan Pathol. 43(9): 776-80, Sep 2016.

128. Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R,

Payne AS, Chu EY.: Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 43(9): 787-91, Sep 2016.

129. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee

DS, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ.: Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell 167(6): 1540-1554, Dec 2016.

130. Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, McGettigan S,

Schuchter LM, Fecher LA: Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer. 2016.

131. Wilson MA, Schuchter LM.: Chemotherapy for Melanoma. Cancer Treat Res. 167:

209-29, 2016. 132. Weber JS, Levit LA, Adamson PC, Bruinooge SS, Burris HA 3rd, Carducci MA,

Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM.: Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. J Clin Oncol 35(2): 139-140, Jan 2017.

133. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, Beqiri M, Liu Q, Xu W,

Garman B, Nathanson KL, Xu X, Karakousis GC, Mills GB, Lu Y, Ahmed TA, Poulikakos PI, Caponigro G, Boehm M, Peters M, Schuchter LM, Weeraratna AT, Herlyn M.: Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 22(7): 1592-602, Apr 2017.

134. Alexander C. Huang, Michael A. Postow, Robert J. Orlowski, Rosemarie Mick,

Bertram Bengsch, Sasikanth Manne, Wei Xu, Shannon Harmon, Josephine R. Giles, Brandon Wenz, Matthew Adamow, Deborah Kuk, Katherine S. Panageas, Cristina Carrera, Phillip Wong, Felix Quagliarello, Bradley Wubbenhorst, Kurt D'Andrea, Kristen E. Pauken, Ramin S. Herati, Ryan P. Staupe, Jason M. Schenkel, Suzanne McGettigan, Shawn Kothari, Sangeeth M. George, Robert H. Vonderheide, Ravi K. Amaravadi, Giorgos C. Karakousis, Lynn M. Schuchter, Xiaowei Xu, Katherine L. Nathanson, Jedd D. Wolchok, Tara C. Gangadhar, E. John Wherry: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545(7652): 60-65, May 2017.

135. Hezhe Lu, Shujing Liu, Gao Zhang, Bin Wu, Yueyao Zhu, Dennie T. Frederick, Yi


Hu, Wenqun Zhong, Sergio Randell, Norah Sadek, Wei Zhang, Gang Chen, Chaoran Cheng, Jingwen Zeng, Lawrence W. Wu, Jie Zhang, Xiaoming Liu, Wei Xu, Clemens Krepler, Katrin Sproesser, Min Xiao, Benchun Miao, Jianglan Liu, Claire D. Song, Jephrey Y. Liu, Giorgos C. Karakousis, Lynn M. Schuchter, Yiling Lu, Gordon Mills, Yusheng Cong, Jonathan Chernoff, Jun Guo, Genevieve M. Boland, Ryan J. Sullivan, Zhi Wei, Jeffrey Field, Ravi K. Amaravadi, Keith T. Flaherty, Meenhard Herlyn, Xiaowei Xu, Wei Guo: PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas. Nature 550(7674): 133-136, Oct 2017.

136. Clemens Krepler, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Bradley

Garman, Min Xiao, Batool Shannan, Andrea Watters, Michela Perego, Gao Zhang, Adina Vultur, Xiangfan Yin, Qin Liu, Ioannis N Anastopoulos, Bradley Wubbenhorst, Melissa A. Wilson, Wei Xu, Giorgos Karakousis, Michael Feldman, Xiaowei Xu, Ravi Amaravadi, Tara C. Gangadhar, David E. Elder, Lauren E. Haydu, Jennifer A. Wargo, Michael A. Davies, Yiling Lu, Gordon B. Mills, Dennie T. Frederick, Michal Barzily-Rokni, Keith T. Flaherty, Dave S. Hoon, Michael Guarino, Joseph J. Bennett, Randall W. Ryan, Nicholas J Petrelli, Carol L. Shields, Mizue Terai, Takami Sato, Andrew E. Aplin, Alexander Roesch, David Darr, Steve Angus, Rakesh Kumar, Ensar Halilovic, Giordano Caponigro, Sebastien Jeay, Jens Wuerthner, Annette Walter, Matthias Ocker, Matthew B. Boxer, Lynn Schuchter, Katherine L. Nathanson, Meenhard Herlyn: A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma. Cell Rep. 21(7): 1953-1967, Nov 2017.

137. Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y,

Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, Davies MA, Herlyn M, Nathanson KL.: Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Rep 21(7): 1936-1952, Nov 2017.

138. Rajasekharan Somasundaram, Gao Zhang, Mizuho Fukunaga-Kalabis, Michela

Perego, Clemens Krepler, Xiaowei Xu, Christine Wagner, Denitsa Hristova, Jie Zhang, Tian, Zhi Wei, Qin Liu, Kanika Garg, Johannes Griss, Rufus Hards, Margarita Maurer, Christine Hafner, Marius Mayerhöfer, Georgios Karanikas, Ahmad Jalili, Verena Bauer-Pohl, Felix Weihsengruber, Klemens Rappersberger, Josef Koller, Roland Lang, Courtney Hudgens, Guo Chen, Michael Tetzlaff, Lawrence Wu, Dennie Tompers Frederick, Richard A. Scolyer, Georgina V. Long, Manashree Damle, Courtney Ellingsworth, Leon Grinman, Harry Choi, Brian J. Gavin, Margaret Dunagin, Arjun Raj, Nathalie Scholler, Laura Gross, Marilda Beqiri, Keiryn Bennett, Ian Watson, Helmut Schaider, Michael A. Davies, Jennifer Wargo, Brian J. Czerniecki, Lynn Schuchter, Dorothee Herlyn, Keith Flaherty, Meenhard Herlyn, Stephan N. Wagner: Tumor-associated B-cells


induce tumor heterogeneity and therapy resistance. Nat Commun 8, 2017.

139. Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM, Melenhorst JJ, Kulikovskaya I,

Brennan AL, Liu X, Lacey SF, Posey AD Jr, Williams AD, So A, Conejo-Garcia JR, Plesa G, Young RM, McGettigan S, Campbell J, Pierce RH, Matro JM, DeMichele AM, Clark AS, Cooper LJ, Schuchter LM, Vonderheide RH, June CH.: Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunol Res 5(12): 1152-1161, Dec 2017.

140. Clinton Yam, Xiaowei Xu, Michael A. Davies, Phyllis A. Gimotty, Jennifer J.D.

Morrissette, Michael T. Tetzlaff, Khalida M. Wani, Shujing Liu, Wanleng Deng, Meghan Buckley, Jianhua Zhao, Ravi K. Amaravadi, Naomi B. Haas, Ragini R. Kudchadkar, Anna C. Pavlick, Jeffrey A. Sosman, Hussein Tawbi, Luke Walker, Lynn M. Schuchter, Giorgos C. Karakousis, Tara C. Gangadhar: A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors. Clin Cancer Res. 24(1): 22-32, Jan 2018.

141. Sinnamon AJ, Neuwirth MG, Gimotty PA, Gangadhar TC, Amaravadi RK,

Schuchter LM, Karakousis GC: Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy with Survival in Patients with Stage IV Melanoma. JAMA Oncol 4(1): 126-128, Jan 2018.

142. Handley NR, Schuchter LM, Bekelman JE.: Best Practices for Reducing Unplanned

Acute Care for Patients with Cancer. J Oncol Pract 14(5): 306-313, May 2018. 143. Ileabett M Echevarríaâ€�Vargas, Patricia I Reyesâ€�Uribe, Adam N Guterres,

Xiangfan Yin, Andrew V Kossenkov, Qin Liu, Gao Zhang, Clemens Krepler, Chaoran Cheng, Zhi Wei, Rajasekharan Somasundaram, Giorgos Karakousis, Wei Xu, Jennifer JD Morrissette, Yiling Lu, Gordon B Mills, Ryan J Sullivan, Miao Benchun, Dennie T Frederick, Genevieve Boland, Keith T Flaherty, Ashani T Weeraratna, Meenhard Herlyn, Ravi Amaravadi, Lynn M Schuchter, Christin E Burd, Andrew E Aplin, Xiaowei Xu, Jessie Villanueva: Coâ€�targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor€�resistant melanoma. EMBO Mol Med. 10(5), May 2018.

144. Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA,

George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, Vonderheide RH.: Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 7(10), Aug 2018.

145. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun

H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan


R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560(7718): 382-386, Aug 2018.

146. Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC,

Ming ME, Chu EY.: Timing of Onset of Adverse Cutaneous Reactions Associated with Programmed Cell Death Protein 1 Inhibitor Therapy. JAMA Dermatol 154(9): 1057-1061, Sep 2018.

147. Ying Zhang, Raj Kurupati, Ling Liu, Xiang Yang Zhou, Gao Zhang, Abeer

Hudaihed, Flavia Filisio, Wynetta Giles-Davis, Xiaowei Xu, Giorgos C. Karakousis, Lynn M. Schuchter, Wei Xu, Ravi Amaravadi, Min Xiao, Norah Sadek, Clemens Krepler, Meenhard Herlyn, Gordon J Freeman, Joshua D Rabinowitz, Hildegund CJ Ertl: Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell. 32(3): 377--391, Sep 2018.

148. Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C,

Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW.: Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res 24(19): 4771-4784, Oct 2018.

149. Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT,

Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH.: A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer 119(10): 1200-1207, Nov 2018.

150. Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A,

McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, Lee JJ, Schuchter LM, Xu X, Herlyn M, Marmorstein R, Gimotty PA, Speicher DW, Winkler JD, Amaravadi RK.: PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. Cancer Discov. Nov 2018.

151. Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude

CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK: ER


translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov Dec 2018.

152. Parekh V, Sobanko J, Miller CJ, Karakousis G, Xu W, Letrero R, Elenitsas R, Xu X,

Elder DE, Amaravadi R, Schuchter LM, Nathanson KL, Wilson MA, Chu EY: NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. J Cutan Pathol Dec 2018.

153. Sarvi S, Crispin R, Lu Y, Zeng L, Hurley TD, Houston DR, von Kriegsheim A,

Chen CH, Mochly-Rosen D, Ranzani M, Mathers ME, Xu X, Xu W, Adams DJ, Carragher NO, Fujita M, Schuchter L, Unciti-Broceta A, Brunton VG, Patton EE.: ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells. Cell Chem Biol. 25(12): 1456-1469, Dec 2018.

154. Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S,

Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W.: Author Correction: PAK signaling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature 565(7738), Jan 2019.

155. Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A,

McAfee Q, McLaughlin NP, Zhang G, Goldman AR, Ojha R, Piao S, Noguera-Ortega E, Martorella A, Alicea GM, Lee JJ, Schuchter LM, Xu X, Herlyn M, Marmorstein R, Gimotty PA, Speicher DW, Winkler JD, Amaravadi RK.: PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. Cancer Discov. 9(2): 220-229, Feb 2019.

156. Akosua A. Nti, Leona W. Serrano, Harpal S. Sandhu, Katherine E. Uyhazi, Ilaina D.

Edelstein, Elaine J. Zhou, Scott Bowman, Delu Song, Tara C. Gangadhar, Lynn M. Schuchter, Sheryl Mitnick, Alexander Huang, Charles W. Nichols, Ravi K. Amaravadi, Benjamin J. Kim, Tomas S. Aleman: FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. Retina. 39(3): 502-513, Mar 2019.

157. Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA,

Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC.: A single dose of


neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 25(3): 454-461, Mar 2019.

158. Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude

CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK.: ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discov. 9(3): 396-415, Mar 2019.

159. Parekh V, Sobanko J, Miller CJ, Karakousis G, Xu W, Letrero R, Elenitsas R, Xu X,

Elder DE, Amaravadi R, Schuchter LM, Nathanson KL, Wilson MA, Chu EY.: NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. J Cutan Pathol. 46(3): 190-194, Mar 2019.

160. Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang

AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ.: TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571(7764), Jul 2019.

161. Song Y, Tieniber AD, Gimotty PA, Mitchell TC, Amaravadi RK, Schuchter LM,

Fraker DL, Karakousis GC: Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. Ann Surg Oncol. Jul 2019.

162. Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C,

Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Rubinstein MP, Schuchter LM, Mitchell TC, Liu Q, Stone EL.: Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control. Cancer Immunol Res 7(8): 1371-1380, Aug 2019.

163. Parikh RB, Manz C, Chivers C, Regli SH, Braun J, Draugelis ME, Schuchter LM,

Shulman LN, Navathe AS, Patel MS, O'Connor NR: Machine Learning Approaches to Predict 6-Month Mortality Among Patients with Cancer JAMA Netw Open. 2(10), Oct 2019.

164. Marie R. Webster, Mitchell E. Fane, Gretchen M. Alicea, Subhasree Basu, Andrew

V. Kossenkov, Gloria E. Marino, Stephen M. Douglass, Amanpreet Kaur, Brett L. Ecker, Keerthana Gnanapradeepan, Abibatou Ndoye, Curtis Kugel, Alexander Valiga, Jessica Palmer, Qin Liu, Xiaowei Xu, Jessicamarie Morris, Xiangfan Yin, Hong Wu, Wei Xu, Cathy Zheng, Giorgos C. Karakousis, Ravi K. Amaravadi, Tara C. Mitchell, Filipe V. Almeida, Min Xiao, Vito W. Rebecca, Ying-Jie Wang, Lynn M. Schuchter, Meenhard Herlyn, Maureen E. Murphy, Ashani T. Weeraratna: Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Mol Cell. 77(3): 633-644, Feb 2020.


165. Manz CR, Parikh RB, Evans CN, Chivers C, Regli SH, Bekelman JE, Small D,

Rareshide CAL, O'Connor N, Schuchter LM, Shulman LN, Patel MS: Integrating machine-generated mortality estimates and behavioral nudges to promote serious illness conversations for cancer patients: Design and methods for a stepped-wedge cluster randomized controlled trial Contemp Clin Trials. Mar 2020.

166. Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, Casella V,

Ngiow SF, Khan O, Huang YJ, Yan P, Nzingha K, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Huang AC, Wherry EJ: Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms Immunity 52(5): 825-841, May 2020.

167. Song Y, Straker RJ 3rd, Xu X, Elder DE, Gimotty PA, Huang AC, Mitchell TC,

Amaravadi RK, Schuchter LM, Karakousis GC: Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma Ann Surg Oncol. 27(8): 2915-2926, Aug 2020.

168. Kersh AE, Schuchter LM, Elenitsas R, Chu EY: Hypohidrosis as an immune-related

adverse event of checkpoint inhibitor therapy. Immunotherapy 12(13): 952-656, Sep 2020.

169. Manz CR, Chen J, Liu M, Chivers C, Regli SH, Braun J, Draugelis M, Hanson CW,

Shulman LN, Schuchter LM, O'Connor N, Bekelman JE, Patel MS, Parikh RB: Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients with Cancer JAMA Oncol. 6(11): 1723-30, Sep 2020.

170. Manz CR, Parikh RB, Small DS, Evans CN, Chivers C, Regli SH, Hanson CW,

Bekelman JE, Rareshide CAL, O'Connor N, Schuchter LM, Shulman LN, Patel MS.: Effect of Integrating Machine Learning Mortality Estimates with Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients with Cancer: A Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Oncol. 6(12), Oct 2020.

171. Manz CR, Chen J, Liu M, Chivers C, Regli SH, Braun J, Draugelis M, Hanson CW,

Shulman LN, Schuchter LM, O'Connor N, Bekelman JE, Patel MS, Parikh RB: Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients with Cancer. JAMA Oncol. 6(11), 2020.

172. Manz CR, Parikh RB, Small DS, Evans CN, Chivers C, Regli SH, Hanson CW,

Bekelman JE, Rareshide CAL, O'Connor N, Schuchter LM, Shulman LN, Patel MS.: Effect of Integrating Machine Learning Mortality Estimates with Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients with Cancer: A Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Oncol. 6(12), Dec 2020.


173. Taekyoung Kwak, Fang Wang, Hui Deng, Thomas Condamine, Vinit Kuma,

Michela Perego, Andrew Kossenkov Luis J Montaner, Xiaowei Xu, Wei Xu, Cathy Zheng , Lynn M Schuchter, Ravi K Amaravadi, Tara C Mitchell, Giorgos C Karakousis, Charles Mulligan, Brian Nam, Gregory Masters, Neil Hockstein, Joseph Bennett, Yulia Nefedova, Dmitry I Gabrilovich: Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Cell Rep. 33(13), Dec 2020.

174. Maity A, Mick R, Rengan R, Mitchell TC, Amaravadi RK, Schuchter LM, Pryma

DA, Patsch DM, Maity AP, Minn AJ, Vonderheide RH, Lukens JN.: A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. Oncoimmunology. 10(1), Jan 2021.

175. Sun L, Surya S, Goodman NG, Le AN, Kelly G, Owoyemi O, Desai H, Zheng C,

DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick ME, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A.: SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy. medRxiv. Jan 2021.

176. Mohiuddin JJ, Chu B, Facciabene A, Poirier K, Wang X, Doucette A, Zheng C, Xu

W, Anstadt EJ, Amaravadi RK, Karakousis GC, Mitchell TC, Huang AC, Shabason JE, Lin A, Swisher-McClure S, Maity A, Schuchter LM, Lukens JN: Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy J. Natl Cancer Inst. 113(2): 162-170, Feb 2021.

177. Godse R, Mcgettigan S, Schuchter LM, Ellebrecht CT, Chu EY: Vogt-Koyanagi-

Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy. Clin Exp Dermatol. Apr 2021.

178. McLane LM, Ngiow SF, Chen Z, Attanasio J, Manne S, Ruthel G, Wu JE, Staupe

RP, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Huang AC, Freedman BD, Betts MR, Wherry EJ.: Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Rep. 35 (6), May 2021.

179. Ou L, Wang H, Liu Q, Zhang J, Lu H, Luo L, Shi C, Lin S, Dong L, Guo Y, Huang

L, Zhu J, Yin X, Huang AC, Karakousis G, Schuchter L, Amaravadi R, Zheng C, Fan Y, Guo W, Xu X.: Dichotomous and stable gamma delta T-cell number and function in healthy individuals. J Immunother Cancer. 9(5), May 2021.


180. Sun L, Surya S, Goodman NG, Le AN, Kelly G, Owoyemi O, Desai H, Zheng C,

DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick ME, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A: SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncol Pract. Jun 2021.

Research Publications, peer-reviewed reviews: 1. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL,

Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ: American Society of Clinical Oncology.: Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. Epub 2006 Dec 8, 25(1): 146-62, Jan 1 2007.

2. Herlyn M, Halaban R, Ronai Z, Schuchter L, Berwick M, Pinkel D.: Roadmap for New

Opportunities in Melanoma Research. Semin Oncol 34(6): 566-576, Dec 2007. 3. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J,

Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Licher AS.: Clinical Cancer Advances 2007: Major research advances in cancer treatment and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 26(2): 313-325, Jan 2008.


Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH: Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 30(23): 2912-18, Aug 2012 Notes: Epub 2012 Jul 9. Review.

5. Harpal S. Sandhu, Anton M. Kolomeyer, Marisa K. Lau, Carol L. Shields, Lynn M.

Schuchter, Charles W. Nichols, Tomas S. Aleman: Acute Exudative Paraneoplastic Polymorphous Vitelliform Maculopathy During Vemurafenib and Pembrolizumab Treatment for Metastatic Melanoma. J Cutan Pathol. 46(3), Mar 2019.

Contributions to peer-reviewed research publications, participation cited but not by

authorship: [none]


Research Publications, non-peer reviewed: 1. Schuchter, L.M., Luginbuhl, W.E., Meropol, N.J.: The Current Status of Toxicity

Protectants in Cancer Therapy. Semin Oncol 19(6): 742-751, 1992. 2. Schuchter, L.M.: Atypical Nevi, Dysplastic Nevi. Hem Onc Annals 1: 256-260, 1993. 3. Herlyn, M., and Schuchter, L.: Gene Therapy of Melanoma: Strategies and

Perspectives. Skin Cancer Foundation Journal 14: 41-43, 1996. 4. Schuchter, L.M.: Guidelines on the Administration of Amifostine. Semin Oncol 23(4

Supp 8): 40-43, 1996. 5. Schuchter, L.M.: Exploration of Platinum-Based Dose Intensive Chemotherapy

Strategies with Amifostine (Ethyol). Eur J Cancer 32A(Supp 4): S40-S42, 1996. 6. Halpern, A. and Schuchter, L.M: Prognostic Models in Primary Melanoma. Semin

Oncol 24(1 Supp 4): S2-S7, 1997. 7. Schuchter, L.M: Current Role of Protective Agents in Cancer Treatment. Oncology 11:

505-516, 1997. 8. Elenitsas, R., Schuchter, L.M: The Role of the Pathologist in the Diagnosis of

Melanoma. Curr Opin Oncol 10(2): 162-169, 1998. 9. Green, R., Schuchter, L.M: Systemic Treatment of Metastatic Melanoma with

Chemotherapy. Hemato Oncol Clin of North Am. W.B. Saunders, 12(4): 863-875, 1998.

10. Hershock, D., Schuchter, L.M.: Angiogenesis Inhibitors: Is This the Future of

Cancer Therapy. Current Practice of Medicine 1(3), 1998. 11. DiPaola, R., Schuchter, L.M: Neurologic protection by Amifostine for

Cytoprotection. Semin Oncol 26(2): 82-88, 1999. 12. Hershock, D., and Schuchter, L.M: Platelet Growth Factors: From the Laboratory to

the Clinic. Infections in Medicine 16(3): 183-188, 1999. 13. Sabir, S., James, W., Schuchter, L.: Cutaneous Manifestations of Cancer. Curr Opin

Oncol 11(2): 139-144, 1999. 14. Shaw, L.M., Bonner, H.S., Schuchter, L., Schiller, J., Lieberman, R.:

Pharmacokinetics of Amifostine: Effects of Dose and Method of Administration. Semin Oncol 26(2 Suppl 7): 34-36, 1999.

15. Schuchter, L.M., Green, R., Fraker, D: Malignant Melanoma of the Gastrointestinal

Tract: Primary and Metastatic Disease. Curr Opin Oncol 12: 181-185, 2000.


16. Schuchter, L.M., Haller, D.G: Update in Oncology. Ann Intern Med 133: 615-621,

2000. 17. Schuchter, L.M.: Review of the 2001 AJCC Staging System for Cutaneous Malignant

Melanoma. Curr Oncol Rep 3(4): 332-337, 2001. 18. Sondak V.K., Ross, M.I., Schuchter, L.M: Early Stage (I, II, III) Melanoma. Curr

Treat Options Oncol 2(3): 183-191, 2001. 19. Sun, W., Schuchter, L.M: Treatment of Metastatic Melanoma. Curr Treat Options

Oncol 2(3): 193-202, 2001. 20. Alley, E., Green, R., Schuchter, L: Cutaneous Toxicities of Cancer Therapy. Curr

Opin Oncol 14(2): 212-216, 2002. 21. Hollis, G., Recio, A., Schuchter, L.: Diagnosis and Management of High-Risk and

Metastatic Melanoma. Seminars in Oncology Nursing 19(1): 32-42, February 2003.

Abstracts (Last 3 years): [none] Editorials, Reviews, Chapters, including participation in committee reports (print or other

media): 1. Schuchter, L.M: Complications of Breast Cancer. Breast Cancer Treatment: A

Comprehensive Guide for Management. B. Fowble (eds.). Mosby, 1991. 2. Guerry, D., Schuchter, L.M: Disseminated Melanoma: A New Standard Therapy?

NEJM 327(8): 560-561, 1992. 3. Schuchter, LM: Paraneoplastic Syndromes. Current Therapy in Oncology. J

Niederhuber (eds.). Mosby, Page: 202-213, 1992. 4. Schuchter, L.M., Glick, J.H: The Current Status of WR-2721 (Amifostine).

Chemotherapy and Radiation Therapy Protector, Biologic Therapy of Cancer Updates. JB Lippincott (eds.). 3: 1-10, 1993.

5. Schuchter, L.M. and Guerry, D: Management of Malignant Melanoma. Manual of

Medical Oncology. MacDonald, J.S., Haller, D.G., Mayer RJ (eds.). Lippincott Co, Page: 252-258, 1995.

6. Schuchter, L.M., and Gordon, M.: Review of Cytokines and CSF. Hematology: Basic

Principles and Practice, 2nd Edition. Hoffman P., Benz E.J., Shattil S., Furie B., Cohen (eds.). Churchill Livingstone, Page: 955-983, 1995.


7. Schuchter, L.M: Approach to Patients with Splenomegaly. Textbook of Internal

Medicine, 3rd Edition. Kelley WN (eds.). Lippincott Co, Page: 1263-1267, 1996. 8. Meropol, N., Schuchter, L.M: Dexrazoxane, Article Reviewed. Oncology 11: 1678-

1681, 1997. 9. Schuchter, L.M: Treatment of Early Melanoma. ASCO Educational Book, Annual

Meeting Page: 331-335, 1997. 10. Schuchter, L.M: Melanoma and other Skin Neoplasms, Editorial Overview. Curr

Opin Oncol 9: 175-177, 1997. 11. Schuchter, L.M., Meropol, N., Glick, J.H.: Radiation and Chemotherapy Protectors.

Cancer: Principals & Practice of Oncology. 5th Edition. DeVita, V.T., Hellman, S., and Rosenberg, S.A. (eds.). J.H. Lippincott Company, Philadelphia, PA, 1997.

12. Schuchter, LM: Melanoma and other skin neoplasms. Current Opinion in Oncology

10(2): 151-152, March 1998. 13. Schuchter, L.M: Melanoma and Other Skin Neoplasms, Editorial Overview. Curr

Opin Oncol 10(2): 151-152, 1998. 14. Schuchter, L.M., Green R.: Paraneoplastic Syndromes. Current Practice of Medicine.

2nd Ed. Series Editor R. Bone. Section Editor, D. Ettinger (eds.). 1998. 15. Green, R. and Schuchter, L.M., Meropol, N., Moots, P.L., Thigpen, J.T.:

Gastrointestinal Manifestations of Malignant Melanoma. Textbook of Uncommon Cancer, Second Edition. Raghavan, D., Brecher, M.L., Johnson, D.H (eds.). John Wiley & Sons, Page: 457-462, 1999.

16. Schuchter, L.M., Haluska, F., Fraker, D., Elenitsas, R.: Malignant Melanoma.

Clinical Oncology. Abeloff, Armitage, Lichter, Niederhuber (eds.). Churchill Livingstone, 1999.

17. Schuchter, L.M: Approach to the Patient with Splenomegaly. Textbook of Internal

Medicine, 4th Edition. Humes HD (eds.). Lippincott Williams & Wilkins. NY, NY, Page: 1530-1535, 2000.

18. Schuchter, L.M.: Melanoma and Other Skin Neoplasms. Editorial Overview. Curr

Opin Oncol 12: 157-158, 2000. 19. Alley, E.W., Schuchter, L.M: Paraneoplastic Syndromes. Best Practice of Medicine

2001. 20. Schuchter, L., Ming, M.: Diagnosis and Treatment of Melanoma and Other Skin

Cancers. Cecil Textbook of Medicine 2002.


21. Schuchter, L., Meropol, N., Winer, E., Hensley, M., Somerfield, M.: Reflection &

Reaction: Amifostine and Chemoradiation Therapy: ASCO Responds. Lancet Oncology 4: 593-594, 2003.

22. Schuchter, L.M.: Adjuvant Interferon Therapy for Melanoma: High-dose, Low-

dose, No dose, Which dose? J Clin Oncol 1(22): 7-10, 2004. 23. Schuchter, L.M.: Malignant Melanoma. Oncology MKSAP, 3rd Edition. Cheson,

B.D. (eds.). American Society of Clinical Oncology, Page: 301-318, 2004. 24. Schuchter, LM: 2010: A Target Date for Improving Survival of Patients with

Metastatic Melanoma. ASCO Educational Book. Michael C. Perry, MD (eds.). Lisa Greaves, Spring: 648-649, 2005.

25. Fecher Leslie A, Amaravadi Ravi, Schuchter Lynn M: Effectively targeting BRAF in

melanoma: a formidable challenge. Pigment cell & melanoma research 21(4): 410-1, Aug 2008.

26. Schuchter L and Ming M: Melanoma and Non-Melanoma Skin Cancers. Cecil

Medicine Lee Goldman and Dennis Ausiello (eds.). Saunders Elsevier, 23rd Edition: 1526-1532, 2008.

27. Schuchter LM: Malignant Melanoma. Oncology MKSAP4th Edition. Anne Moore

(eds.). American Society of Clinical Oncology, 2008. 28. Fecher Leslie A, Amaravadi Ravi K, Schuchter Lynn M, Flaherty Keith T: Drug

targeting of oncogenic pathways in melanoma. Hematology/oncology clinics of North America 23(3): 599-618, x, Jun 2009.

29. T Gangadhar and L Schuchter: Adjuvant Therapy for Melanoma. Sharfman, William

(eds.). Demos Medical Publishing 3(3): 471-184, 2012. 30. T Gangadhar, LA Fecher, C Miller, G Karakousis, R Vonderheide, G Xu, LM

Schuchter: Melanoma. Abeloff's Clinical Oncology, 5th Edition 2013. 31. Diamond, M, Gangadhar, T, Schuchter, L.M.: Immunotherapy for Melanoma Clinical

Oncology. Abeloff UPDATE 2015. 32. Schuchter, L.M.: Adjuvant Melanoma Therapy: Head Spinning Progress. N Engl J

Med 377: 1888-1889, Nov 2017. 33. L. Kruper and L. Schuchter: Malignant Melanoma and Non-Melanoma Skin Cancer

in the Elderly. Second Edition. Multidisciplinary Treatment and Management of Cancer in the Elderly. Muss HB, Johnson KA, Hunter CP (eds.). Marcel Dekker, In Press.


Books: [none] Alternative Media: 1. Schuchter, L.M.: Melanoma Module PIER: The (Physicians Information & Education

Resource). Online. ACP 2002. Patents: [none]

UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE …

Documents

Transcript of UNIVERSITY OF PENNSYLVANIA - PERELMAN SCHOOL OF MEDICINE …